To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 258 participants.

Also called NCT05075408

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 258 participants (enrolled count) (from the registry)
Sponsor
Galderma R&D (from the registry)
Registry
  • NCT NCT05075408
  • EudraCT 2021-004766-35
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Hungary, Poland, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05075408. Randomized; double masking; primary purpose treatment. Start 2022-03-18 (actual); primary completion 2024-01-04 (actual). Results posted on 2025-02-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
Acronym
NIKAIA 1
Condition
Chronic Kidney Disease Associated Moderate to Severe Pruritus
Intervention (Drug)
Nemolizumab
Intervention (Drug)
Nemolizumab
Intervention (Drug)
Placebo
Lead sponsor
Galderma R&D (class: industry)

Record details

Record id
cardio:ct-nct05075408
Content hash
17e85f0514607b2ae3f42a48eaf5ac91c950c14341598922dbc8956b264f8a84